CONCLUSION:
The addition of clinical pharmacist services to cardiac rehabilitation
program had resulted in marked decrease in hs-CRP, LVESV and LVEDV.
Future studies are required to confirm our results. Finally, future
studies are needed to evaluate the impact of clinical
pharmacist-provided services addition to cardiac rehabilitation program
on CVD morbidity and mortality among post-ACS patients.